Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Health Research Projects (NSERC partnered)

University of Toronto

$222,381.00

Tissue engineered patches for the repair of cardiovascular congenital malformations

EF 2009-10

Résumé
Congenital malformations of the heart are the most frequent birth defects affecting 1/1000 newborns. Currently, the defects are repaired with inert non-degradable materials: Dacron and Gore-Tex. The synthetic materials may become thrombogenic or infected and do not grow with the child necessitating reoperations. Ideal replacement would be a vascularized contractile patch consisting of patient's own cells. Our objective is to engineer a living cardiac patch based on bone marrow cells, already in clinic, and promising patient specific induced pluripotent stem cells (iPSC). Our platform will be a biocompatible and biodegradable collagen scaffolds with covalently immobilized growth factors. Our factors of choice are VEGF and bFGF. The combined use of VEGF and bFGF is expected to affect both angiogenesis and arteriogenesis, thus resulting in the stable vasculature. The selected growth factors were proven to be critical for differentiation of KDR+ human cardiovascular progenitors into cardiomyocytes as well as the bone marrow c-kit+ cells into cardiac-like cells. Covalent immobilization will enable localized action and sustained signaling required for rapid vascularization and efficient differentiation of progenitors. In preliminary rat studies, the scaffold with immobilized VEGF implanted into the right ventricular outflow tract (RVOT) defect exhibited improved angiogenesis, maintenance of thickness, and cell homing to the graft after injection of GFP+ bone marrow cells. Cardiovascular progenitors derived from embryonic stem cells differentiated into endothelial cells using immobilized VEGF. In Aim 1, we will develop more specific ''click'' reaction-based chemistry for covalent immobilization of growth factors to the scaffolds. We will independently control scaffold mechanical properties vs. the amount of immobilized growth factors. We will evaluate the biomaterial in the immunocompetent Leiws rat RVOT defect. In Aim 2, the patches will be seeded with human bone marrow c-kit+ cells or iPSC-derived KDR+ progenitors, cultivated up to 3 weeks and implanted into RVOT defects of nude rats. In situ differentiation via immobilized growth factors will enable con-current formation of both vasculature and myocardium. Samples of right ventricular tissue from pediatric patients (SickKids hospital) will be positive controls. In Aim 3, the most promising patch from Aims 1 or 2 will be evaluated in a large animal model, pigs, as a prelude to full pre-clinical studies.
Programme
Collaborative Health Research Projects (NSERC partnered)
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
198906
Name
Radisic Milica
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Natural Sciences and Engineering Research Council of Canada (NSERC)
Instname2
Unable to allocate
Prcname2
Collaborative Health Research Projects - NSERC Partnered
Projecttitle
Tissue engineered patches for the repair of cardiovascular congenital malformations
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$222,381
Cihrequipment2
$0
Programname2
Collaborative Health Research Projects (NSERC partnered)
Keyworddelim
Cardiac
Abstract
Congenital malformations of the heart are the most frequent birth defects affecting 1/1000 newborns. Currently, the defects are repaired with inert non-degradable materials: Dacron and Gore-Tex. The synthetic materials may become thrombogenic or infected and do not grow with the child necessitating reoperations. Ideal replacement would be a vascularized contractile patch consisting of patient's own cells. Our objective is to engineer a living cardiac patch based on bone marrow cells, already in clinic, and promising patient specific induced pluripotent stem cells (iPSC). Our platform will be a biocompatible and biodegradable collagen scaffolds with covalently immobilized growth factors. Our factors of choice are VEGF and bFGF. The combined use of VEGF and bFGF is expected to affect both angiogenesis and arteriogenesis, thus resulting in the stable vasculature. The selected growth factors were proven to be critical for differentiation of KDR+ human cardiovascular progenitors into cardiomyocytes as well as the bone marrow c-kit+ cells into cardiac-like cells. Covalent immobilization will enable localized action and sustained signaling required for rapid vascularization and efficient differentiation of progenitors. In preliminary rat studies, the scaffold with immobilized VEGF implanted into the right ventricular outflow tract (RVOT) defect exhibited improved angiogenesis, maintenance of thickness, and cell homing to the graft after injection of GFP+ bone marrow cells. Cardiovascular progenitors derived from embryonic stem cells differentiated into endothelial cells using immobilized VEGF. In Aim 1, we will develop more specific ''click'' reaction-based chemistry for covalent immobilization of growth factors to the scaffolds. We will independently control scaffold mechanical properties vs. the amount of immobilized growth factors. We will evaluate the biomaterial in the immunocompetent Leiws rat RVOT defect. In Aim 2, the patches will be seeded with human bone marrow c-kit+ cells or iPSC-derived KDR+ progenitors, cultivated up to 3 weeks and implanted into RVOT defects of nude rats. In situ differentiation via immobilized growth factors will enable con-current formation of both vasculature and myocardium. Samples of right ventricular tissue from pediatric patients (SickKids hospital) will be positive controls. In Aim 3, the most promising patch from Aims 1 or 2 will be evaluated in a large animal model, pigs, as a prelude to full pre-clinical studies.
Competitiondate
200910
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Radisic, Milica
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $222,381~ $0~